{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:30:09Z","timestamp":1769106609066,"version":"3.49.0"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013302","name":"King Abdullah International Medical Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioinform."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sickle cell disease (SCD) is an inherited blood disorder characterized by chronic hemolysis, inflammation, and vaso-occlusive crises (VOC), leading to multiple complications and reduced life expectancy in affected individuals. Limited effective treatment options are currently available; however, recent genomic findings from underrepresented populations (Saudi Arabians) have offered new hope for predicting molecularly guided treatments. This study aimed to identify approved drugs suitable for repurposing based on their interactions with SCD-associated genetic variants and to discover novel druggable targets within genetic pathways linked to disease severity by utilizing genome-wide association study (GWAS) data from Saudi SCD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bioinformatic pipelines were used to evaluate drug-gene interactions and identify potential therapeutic targets based on GWAS data derived from the Saudi population. Approved drugs were suggested for repurposing according to their interactions with genes known to impact SCD pathophysiology, using the Drug-Gene Interaction Database (DGIdb 5.0). New drug targets were also proposed by assessing the simulated binding pockets of gene products, using 3D protein structures from the Protein Data Bank (PDB) and the AlphaFold database. Molecules with higher druggability scores, as estimated by the DoGSiteScorer database, were predicted to have a higher success rate for new SCD treatment development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our analysis identified 78 approved medications with potential for repurposing in SCD; this list was narrowed to 21 candidates based on safety profiles and interactions with key genetic pathways. Among these, simvastatin, allopurinol, omalizumab, canakinumab, and etanercept were suggested as the most promising agents. Furthermore, novel drug targets encoded by olfactory receptor (OR) gene clusters (OR51V1, OR52A1, OR52A5, OR51B5, and OR51S1), TRIM genes, SIDT2, and CADM3 displayed high druggability scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides a robust framework for drug repurposing and novel drug discovery in SCD, particularly tailored to the Saudi population. The findings underscore the potential of leveraging genomic data to identify targeted therapies, offering a pathway to more personalized and effective treatments for SCD patients. Future clinical trials are essential to validate these findings and translate them into clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fbinf.2025.1671626","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:27:43Z","timestamp":1764656863000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Genomics-driven drug repurposing and novel targets identification for sickle cell disease in Saudi patients"],"prefix":"10.3389","volume":"5","author":[{"given":"Ali","family":"Alghubayshi","sequence":"first","affiliation":[]},{"given":"Mohammad A.","family":"Alshabeeb","sequence":"additional","affiliation":[]},{"given":"Dayanjan","family":"Wijesinghe","sequence":"additional","affiliation":[]},{"given":"Mohammed","family":"AlAwadh","sequence":"additional","affiliation":[]},{"given":"Suad","family":"Alshammari","sequence":"additional","affiliation":[]},{"given":"Khalifa","family":"Alrajeh","sequence":"additional","affiliation":[]},{"given":"Mona A.","family":"Alkhairi","sequence":"additional","affiliation":[]},{"given":"Imadul","family":"Islam","sequence":"additional","affiliation":[]},{"given":"Ahmed","family":"Alaskar","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/pbc.24443","article-title":"Potential role for statins in sickle cell disease","volume":"60","author":"Adam","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"bcr1020114889","DOI":"10.1136\/bcr.10.2011.4889","article-title":"Juvenile idiopathic arthritis coexisting with sickle cell disease: two case reports","volume":"2011","author":"Adelowo","year":"2011","journal-title":"BMJ Case Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/dtb.2024.256956rep","article-title":"Statin-induced debilitating weakness and myopathy","volume":"63","author":"Ademi","year":"2025","journal-title":"Drug Ther. Bull."},{"key":"B4","article-title":"Tumor lysis syndrome","volume-title":"StatPearls","author":"Adeyinka","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13398","DOI":"10.1038\/s41598-023-40160-2","article-title":"Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management","volume":"13","author":"Agu","year":"2023","journal-title":"Sci. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/rth2.12378","article-title":"Determination of von Willebrand factor level in patient with sickle cell diseasein vaso-occlusive crisis","volume":"4","author":"Akaba","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"B7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.5144\/0256-4947.2006.487","article-title":"Patterns of mortality in adult sickle cell disease in Al-Hasa region of Saudi Arabia","volume":"26","author":"Al-Suliman","year":"2006","journal-title":"Ann. Saudi Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.3390\/ijms26062817","article-title":"Unraveling the complex genomic interplay of sickle cell disease among the Saudi population: a case-control GWAS analysis","volume":"26","author":"Alghubayshi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e38817","DOI":"10.7759\/cureus.38817","article-title":"Predictors of mortality in adults with sickle cell disease admitted to the intensive care unit in king saud medical city, Saudi Arabia","volume":"15","author":"Alhaj","year":"2023","journal-title":"Cureus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3390\/genes14101919","article-title":"Impact of genetic variations on thromboembolic risk in Saudis with sickle cell disease","volume":"14","author":"Alshabeeb","year":"2023","journal-title":"Genes (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jaci.2010.12.1114","article-title":"Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidity","volume":"127","author":"An","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/blood-2014-01-543652","article-title":"Acid sphingomyelinase is activated in sickle cell erythrocytes and contributes to inflammatory microparticle generation in SCD","volume":"124","author":"Awojoodu","year":"2014","journal-title":"Blood"},{"key":"B13","volume-title":"ASCENT1: a phase 2 trial to evaluate the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease","year":"2024"},{"key":"B15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bjhh.2017.08.008","article-title":"Genetic, laboratory and clinical risk factors in the development of overt ischemic stroke in children with sickle cell disease","volume":"40","author":"Belis\u00e1rio","year":"2018","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1471-2350-8-S1-S11","article-title":"Genome-wide association with select biomarker traits in the framingham heart study","volume":"8","author":"Benjamin","year":"2007","journal-title":"BMC Med. Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3324\/haematol.2011.054957","article-title":"Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia","volume":"97","author":"Bereal-Williams","year":"2012","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","first-page":"D301","DOI":"10.1093\/nar\/gkl971","article-title":"The worldwide protein data bank (wwPDB): ensuring a single, uniform archive of PDB data","volume":"35","author":"Berman","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/IJGM.S393233","article-title":"The burden of sickle cell disease in Saudi Arabia: a single-institution large retrospective study","volume":"16","author":"Bin Zuair","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"14560","DOI":"10.1073\/pnas.97.26.14560","article-title":"Comparative structural and functional analysis of the olfactory receptor genes flanking the human and mouse beta-globin gene clusters","volume":"97","author":"Bulger","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2217\/pgs.13.81","article-title":"Pharmacogenomics in early-phase clinical development","volume":"14","author":"Burt","year":"2013","journal-title":"Pharmacogenomics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/d41586-024-03214-7","article-title":"Chemistry nobel goes to developers of AlphaFold AI that predicts protein structures","volume":"634","author":"Callaway","year":"2024","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"D1227","DOI":"10.1093\/nar\/gkad1040","article-title":"DGIdb 5.0: rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms","volume":"52","author":"Cannon","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/jcp.25929","article-title":"The diversified function and potential therapy of ectopic olfactory receptors in non-olfactory tissues","volume":"233","author":"Chen","year":"2018","journal-title":"J. Cell Physiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10557-024-07580-2","article-title":"Transporter genes and statin-induced hepatotoxicity","volume":"39","author":"Choi","year":"2025","journal-title":"Cardiovasc Drugs Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"102941","DOI":"10.1016\/j.redox.2023.102941","article-title":"Fatty acid nitroalkenes - multi-target agents for the treatment of sickle cell disease","volume":"68","author":"Chowdhury","year":"2023","journal-title":"Redox Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"E349","DOI":"10.1002\/ajh.27071","article-title":"Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: a worldwide pharmacovigilance study","volume":"98","author":"Contejean","year":"2023","journal-title":"Am. J. Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"891838","DOI":"10.3389\/fphar.2022.891838","article-title":"Distribution of HLA-B alleles and haplotypes in Qatari: recommendation for establishing pharmacogenomic markers screening for drug hypersensitivity","volume":"13","author":"Dashti","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B30","article-title":"Allopurinol therapy and HLA-B*58:01 genotype","volume-title":"Medical genetics summaries","author":"Dean","year":"2012"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e63646","DOI":"10.7759\/cureus.63646","article-title":"Review of AlphaFold 3: transformative advances in drug design and therapeutics","volume":"16","author":"Desai","year":"2024","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"publisher","first-page":"GEI.S2626","DOI":"10.4137\/gei.s2626","article-title":"Sickle cell disease in the post genomic era: a monogenic disease with a polygenic phenotype","volume":"2009","author":"Driss","year":"2009","journal-title":"Genomics Insights"},{"key":"B33","unstructured":"Xolair (omalizumab) FDA Approval History\n          \n          \n          2024"},{"key":"B86","unstructured":"Simvastatin Prices, Coupons & Patient Assistance Programs"},{"key":"B10","unstructured":"Allopurinol Prices, Coupons & Patient Assistance Programs"},{"key":"B48","unstructured":"Ilaris Prices, Coupons & Patient Assistance Programs"},{"key":"B100","unstructured":"Xolair Prices, Coupons & Patient Assistance Programs"},{"key":"B34","unstructured":"An emerging approach in drug discovery | IntechOpen\n          \n          \n          2024"},{"key":"B35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/jmg.32.8.623","article-title":"Consanguinity among the Saudi Arabian population","volume":"32","author":"el-Hazmi","year":"1995","journal-title":"J. Med. Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13075-019-1846-6","article-title":"Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients\u2014Immune-related candidate proteins affected by TNF blocking treatment","volume":"21","author":"Estelius","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"B37","volume-title":"Revocation of authorisation for sickle cell disease medicine adakveo","year":"2023"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1006\/geno.1999.5935","article-title":"An olfactory receptor gene is located in the extended human beta-globin gene cluster and is expressed in erythroid cells","volume":"61","author":"Feingold","year":"1999","journal-title":"Genomics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/14787210.2018.1544490","article-title":"Risk of infection associated with anti-TNF-\u03b1 therapy","volume":"16","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e33702","DOI":"10.1371\/journal.pone.0033702","article-title":"The role of fibrocytes in sickle cell lung disease","volume":"7","author":"Field","year":"2012","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat. Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the global burden of disease study 2021","volume":"10","author":"McHugh","year":"2023","journal-title":"Lancet Haematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41419-021-04453-6","article-title":"Sidt2 is a key protein in the autophagy-lysosomal degradation pathway and is essential for the maintenance of kidney structure and filtration function","volume":"13","author":"Geng","year":"2021","journal-title":"Cell Death Dis."},{"key":"B44","unstructured":"Explore the Adult GTEx data\n          \n          \n          2024"},{"key":"B45","unstructured":"Gene Expression Omnibus\n          \n          \n          2024"},{"key":"B46","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/bjh.14580","article-title":"Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial","volume":"177","author":"Hoppe","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-2141.2010.08480.x","article-title":"A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction","volume":"153","author":"Hoppe","year":"2011","journal-title":"Br. J. Haematol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ijns5020020","article-title":"Sickle cell disease-genetics, pathophysiology, clinical presentation and treatment","volume":"5","author":"Inusa","year":"2019","journal-title":"Int. J. Neonatal Screen."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1515856","DOI":"10.3389\/fimmu.2025.1515856","article-title":"Expression of innate immunity genes in human hematopoietic stem\/progenitor cells - single cell RNA-Seq analysis","volume":"16","author":"Jarczak","year":"2025","journal-title":"Front. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4103\/0256-4947.81540","article-title":"Epidemiology of sickle cell disease in Saudi Arabia","volume":"31","author":"Jastaniah","year":"2011","journal-title":"Ann. Saudi Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"D972","DOI":"10.1093\/nar\/gkad832","article-title":"PharmGWAS: a GWAS-based knowledgebase for drug repurposing","volume":"52","author":"Kang","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"B55","doi-asserted-by":"publisher","first-page":"RP89386","DOI":"10.7554\/eLife.89386","article-title":"How accurately can one predict drug binding modes using AlphaFold models?","volume":"12","author":"Karelina","year":"2023","journal-title":"Elife"},{"key":"B56","doi-asserted-by":"publisher","first-page":"H293","DOI":"10.1152\/ajpheart.01150.2003","article-title":"Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice","volume":"287","author":"Kaul","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle cell disease: a review","volume":"328","author":"Kavanagh","year":"2022","journal-title":"JAMA"},{"key":"B58","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CRD.0b013e318229a908","article-title":"Allopurinol as a cardiovascular drug","volume":"19","author":"Kelkar","year":"2011","journal-title":"Cardiol. Rev."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e2337484","DOI":"10.1001\/jamanetworkopen.2023.37484","article-title":"Genetic variation and sickle cell disease severity: a systematic review and meta-analysis","volume":"6","author":"Kirkham","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/jhg.2010.19","article-title":"The pursuit of genome-wide association studies: where are we now?","volume":"55","author":"Ku","year":"2010","journal-title":"J. Hum. Genet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"D876","DOI":"10.1093\/nar\/gkr1011","article-title":"STITCH 3: zooming in on protein-chemical interactions","volume":"40","author":"Kuhn","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER database of drugs and side effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1457158","DOI":"10.3389\/frhem.2024.1457158","article-title":"Sickle cell disease: a comparative perspective on global and national initiatives","volume":"3","author":"Kumar","year":"2024","journal-title":"Front. Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ymthe.2024.01.015","article-title":"A new frontier: FDA approvals for gene therapy in sickle cell disease","volume":"32","author":"Leonard","year":"2024","journal-title":"Mol. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"734966","DOI":"10.3389\/fimmu.2021.734966","article-title":"NOTCH4 exhibits anti-inflammatory activity in activated macrophages by interfering with Interferon-\u03b3 and TLR4 signaling","volume":"12","author":"L\u00f3pez-L\u00f3pez","year":"2021","journal-title":"Front. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/CVI.00425-07","article-title":"HLA class II haplotypes distinctly associated with vaso-occlusion in children with sickle cell disease","volume":"15","author":"Mahdi","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"103447","DOI":"10.1016\/j.transci.2022.103447","article-title":"Impact of HLA-G +3142C>G on the development of antibodies to blood group systems other than the Rh and Kell among sensitized patients with sickle cell disease","volume":"61","author":"Martins","year":"2022","journal-title":"Transfus. Apher. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e2210779119","DOI":"10.1073\/pnas.2210779119","article-title":"Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease","volume":"119","author":"Metaferia","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s13205-019-2038-4","article-title":"Exploring genetic targets of psoriasis using genome wide association studies (GWAS) for drug repurposing","volume":"10","author":"Nanda","year":"2020","journal-title":"3 Biotech."},{"key":"B69","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat. Genet."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e723","DOI":"10.1016\/S2352-3026(21)00216-7","article-title":"Child mortality from sickle cell disease in Nigeria: a model-estimated, population-level analysis of data from the 2018 demographic and health survey","volume":"8","author":"Nnodu","year":"2021","journal-title":"Lancet Haematol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/d41573-022-00120-3","article-title":"Human genetics evidence supports two-thirds of the 2021 FDA-Approved drugs","volume":"21","author":"Ochoa","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B72","doi-asserted-by":"publisher","first-page":"146077","DOI":"10.1172\/JCI146077","article-title":"Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage","volume":"131","author":"Page","year":"2021","journal-title":"J. Clin. Invest"},{"key":"B73","unstructured":"Pfizer voluntarily withdraws all lots of sickle cell disease treatment OXBRYTA\u00ae (voxelotor) from worldwide markets\n          \n          \n          2024"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.hoc.2022.06.006","article-title":"Genetic modifiers of sickle cell disease","volume":"36","author":"Pincez","year":"2022","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood.V106.11.2325.2325","article-title":"Differential effects of lovastatin and allopurinol therapy in a murine model of sickle cell disease","volume":"106","author":"Pritchard","year":"2005","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3389\/fphar.2017.00896","article-title":"Enhancing the promise of drug repositioning through genetics","volume":"8","author":"Pritchard","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B77","unstructured":"The human protein atlas\n          \n          \n          2024"},{"key":"B78","unstructured":"Introduction and historical overview of drug repurposing opportunities\n          \n          \n            \n              Pushpakom\n              S.\n            \n          \n          \n          2024"},{"key":"B79","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1038\/s41467-023-39335-2","article-title":"Structural insight into the human SID1 transmembrane family member 2 reveals its lipid hydrolytic activity","volume":"14","author":"Qian","year":"2023","journal-title":"Nat. Commun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41576-021-00387-z","article-title":"Advancing the use of genome-wide association studies for drug repurposing","volume":"22","author":"Reay","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1182\/blood.2021013674","article-title":"A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia","volume":"139","author":"Rees","year":"2022","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1089\/crispr.2024.0042","article-title":"Affordable pricing of CRISPR treatments is a pressing ethical imperative","volume":"7","author":"Rueda","year":"2024","journal-title":"CRISPR J."},{"key":"B84","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1160\/TH15-08-0620","article-title":"The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials","volume":"115","author":"Sahebkar","year":"2016","journal-title":"Thromb. Haemost."},{"key":"B85","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fphys.2020.00435","article-title":"Recent advances in the treatment of sickle cell disease","volume":"11","author":"Salinas","year":"2020","journal-title":"Front. Physiol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/ajh.24856","article-title":"A monocyte-TNF-endothelial activation axis in sickle transgenic mice: therapeutic benefit from TNF blockade","volume":"92","author":"Solovey","year":"2017","journal-title":"Am. J. Hematol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/s0198-8859(01)00378-0","article-title":"Infectious complications in sickle cell disease are influenced by HLA class II alleles","volume":"63","author":"Tamouza","year":"2002","journal-title":"Hum. Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41573-018-0003-2","article-title":"Therapeutic strategies for sickle cell disease: towards a multi-agent approach","volume":"18","author":"Telen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e001977","DOI":"10.1161\/CIRCGEN.117.001977","article-title":"Druggability of coronary artery disease risk loci","volume":"11","author":"Tragante","year":"2018","journal-title":"Circ. Genom Precis. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1128\/JVI.01804-12","article-title":"TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity","volume":"87","author":"Uchil","year":"2013","journal-title":"J. Virol."},{"key":"B92","volume-title":"Perspective chapter: technological advances in population genetics","author":"Ullah","year":"2025"},{"key":"B93","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijmedinf.2013.09.004","article-title":"Operational rules for the implementation of INN prescribing","volume":"83","author":"Van Bever","year":"2014","journal-title":"Int. J. Med. Inf."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1093\/bioinformatics\/bts310","article-title":"DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment","volume":"28","author":"Volkamer","year":"2012","journal-title":"Bioinformatics"},{"key":"B95","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware","year":"2017","journal-title":"Lancet"},{"key":"B96","unstructured":"VigiAccess\n          \n          \n          2024"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/vox.13351","article-title":"HLA class II regulation of immune response in sickle cell disease patients: susceptibility to red blood cell alloimmunization (systematic review and meta-analysis)","volume":"117","author":"Wong","year":"2022","journal-title":"Vox Sang."},{"key":"B98","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1096\/fj.04-3218fje","article-title":"Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice","volume":"19","author":"Wood","year":"2005","journal-title":"FASEB J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3390\/antiox13030337","article-title":"Simvastatin-mediated Nrf2 activation induces fetal hemoglobin and antioxidant enzyme expression to ameliorate the phenotype of sickle cell disease","volume":"13","author":"Xi","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"B101","doi-asserted-by":"publisher","first-page":"111717","DOI":"10.1016\/j.celrep.2022.111717","article-title":"Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer\u2019s disease","volume":"41","author":"Xu","year":"2022","journal-title":"Cell Rep."},{"key":"B102","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1186\/1471-2350-8-S1-S12","article-title":"Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the framingham heart study","volume":"8","author":"Yang","year":"2007","journal-title":"BMC Med. Genet."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e0694","DOI":"10.1097\/CCE.0000000000000694","article-title":"Extracorporeal immunomodulation treatment and clinical outcomes in ICU COVID-19 patients","volume":"4","author":"Yessayan","year":"2022","journal-title":"Crit. Care Explor"},{"key":"B104","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Frontiers in Bioinformatics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2025.1671626\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:27:53Z","timestamp":1764656873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2025.1671626\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":104,"alternative-id":["10.3389\/fbinf.2025.1671626"],"URL":"https:\/\/doi.org\/10.3389\/fbinf.2025.1671626","relation":{},"ISSN":["2673-7647"],"issn-type":[{"value":"2673-7647","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"article-number":"1671626"}}